Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20273118 | 0.86 | NPC1 (0.35) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24919732 | 0.84 | ALDH1A1 (0.36) | NPC1RAB9AGRNSORT1IDO1 | |
| SCHEMBL15304182 | 0.84 | ALDH1A1 (0.36) | NPC1RAB9AGRNSORT1IDO1 | |
| SCHEMBL25718332 | 0.82 | IDO1 (0.32) | ACHENPC1RAB9AIDO1ALDH1A1 | |
| SCHEMBL23815815 | 0.80 | NAMPT (0.39) | ACHEALDH1A1HTTL3MBTL1 | |
| SCHEMBL19003524 | 0.79 | IDO1 (0.31) | NPC1RAB9AIDO1ALDH1A1HTT | |
| SCHEMBL20193877 | 0.79 | ACHE (0.39) | ACHEIDO1 | |
| SCHEMBL20122134 | 0.78 | GRN (0.33) | GRNSORT1IDO1ALDH1A1HTT | |
| SCHEMBL26928487 | 0.78 | GRN (0.36) | NPC1RAB9AGRNSORT1IDO1 | |
| SCHEMBL24406265 | 0.78 | ACHE (0.38) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20200339542-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407737-B2 | Inhibitors of RAF kinases | BRAF, RAF1, ARAF | ACHE 4851/4885NPC1 2530/4885RAB9A 1050/4885 |
| US-20200339542-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | ACHE 3481/4885NPC1 3840/4885RAB9A 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.